Antidepressant Long-Term Efficacy Pre-Approval Will Be Voted On By Cmte.
Executive Summary
FDA will ask whether it is reasonable to require both acute and long-term efficacy data in applications for antidepressants and other chronic psychiatric drugs at its Psychopharmacologic Drugs Advisory Committee meeting on Oct. 25